Alnylam reports 60% to 64% mean CSF mutant huntingtin reduction with brezosiran in a Phase 1b Huntington’s disease study. Clinical benefit remains unproven.
Written By: Charvi Kalal, PharmD
Reviewed By: Pharmacally Editorial Team
Alnylam Pharmaceuticals reported initial Phase 1b results for brezosiran (ALN-HTT02), an investigational RNA interference (RNAi) therapy for Huntington’s disease (HD), on October 23, 2026. Across the first five dose cohorts, the company reported dose-dependent reductions in cerebrospinal fluid (CSF) mutant huntingtin (mHTT), including a mean reduction of 60% to 64% at month 3 in the highest-dose group evaluated and a maximum individual reduction of 83%. The findings provide early evidence of target engagement but do not establish clinical benefit.
Phase 1b Study Design
The randomized, double-blind, placebo-controlled Phase 1b trial (NCT06585449) evaluates the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending intrathecal doses of brezosiran. The reported results cover 48 participants across five dose cohorts. A sixth cohort, planned for 12 participants, is still enrolling and has not yet been evaluated.
The study includes adults aged 25 to 70 years with genetically confirmed HD in Stage 2 or early Stage 3 of the Huntington’s Disease Integrated Staging System (HD-ISS). The trial is being conducted in Canada, Germany and the United Kingdom.
Eligible participants may enter an open-label extension (OLE), receiving brezosiran every six months for up to 36 months to assess longer-term safety, sustained target engagement and exploratory measures of disease progression.
Key Results: Target Engagement and Safety
CSF mHTT levels declined in a dose-dependent manner across the first five cohorts, with target engagement confirmed using two independent assays. The mean reduction of 60% to 64% at month 3 in the highest-dose group is the principal reported pharmacodynamic finding. However, CSF mHTT lowering remains a biomarker result and cannot, by itself, establish that the treatment slows neurodegeneration or improves clinical outcomes.
Alnylam also reported an encouraging safety profile among participants followed for up to 12 months. No dose-dependent increases were observed in CSF inflammatory markers, CSF neurofilament light chain (NfL) or brain ventricular volume. The announcement did not provide adverse-event rates or detailed comparative safety results. These findings therefore offer preliminary reassurance on selected measures rather than establishing overall or long-term safety.
Targeting Huntingtin Production
Brezosiran uses Alnylam’s C16 conjugate platform for delivery to the central nervous system and targets exon 1 of huntingtin (HTT) messenger RNA. The strategy is designed to reduce production of different forms of huntingtin, including full-length mutant HTT and the shorter mutant HTT1a protein.
This targeting approach provides a biological rationale for the programme, but the announcement does not report separate quantitative clinical results for HTT1a. Its contribution to disease progression and the clinical consequences of reducing these protein forms remain questions for further research.
Clinical Development and Regulatory Outlook
Alnylam plans to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment, to evaluate whether brezosiran can slow disease progression in adults with Huntington’s disease. The Phase 1b study remains ongoing, with a sixth dose cohort of 12 participants still enrolling and awaiting evaluation.
Eligible participants may also enter the open-label extension, in which brezosiran is administered every six months for up to 36 months. This extension will assess long-term safety, sustained target engagement and exploratory measures of disease progression. The planned pivotal study will need to determine whether the observed biomarker reductions translate into clinically meaningful benefit.
Clinical Interpretation
The Phase 1b findings provide early evidence of target engagement, but the clinical significance of the observed biomarker changes remains uncertain. Lowering CSF mutant huntingtin does not, by itself, establish that brezosiran slows neurodegeneration or alters the course of Huntington’s disease.
The available safety findings are encouraging but preliminary. The absence of dose-dependent changes in selected markers does not exclude other treatment-related adverse events or establish long-term safety. The optimal dose and repeat-dosing schedule also remain undetermined.
The planned pivotal study will be critical in determining whether the pharmacodynamic effect translates into clinically meaningful benefit. Until such evidence is available, brezosiran remains an investigational therapy with promising early pharmacological activity, not an established disease-modifying treatment.
Reference
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington’s Disease. Alnylam Pharmaceuticals, October 23, 2026.
A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease, ClinicalTrials.gov ID NCT06585449
About the Writer
Charvi Kalal (LinkedIn) is a Pharm.D intern and aspiring medical writer with hands-on experience in medical writing, clinical research, pharmacovigilance, and clinical pharmacy. She has experience in medical content writing through CliMed, along with exposure to ADR monitoring, prescription analysis, patient counselling, literature review, and research documentation. Her research focuses on ADR monitoring and reporting in breast cancer patients receiving targeted therapy. With certifications in GCP, biomedical research, scientific writing, and clinical research, she is passionate about transforming scientific evidence into accurate, engaging, and accessible healthcare content.